Judging by the questions the FDA is posing, much of Friday’s Arthritis Advisory Committee (AAC) meeting on Ardea Biosciences Inc.’s gout drug Zurampic will focus on the dosing and safety of the oral drug, in light of what the agency considers its “modest” treatment effect.